



December 13, 2016

Arena Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- [Arena Pharmaceuticals, Inc.](#) (NASDAQ: ARNA) today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate update at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 9:00am PT. The conference will take place January 9-12, 2017, at the Westin St. Francis in San Francisco, CA.

A live audio webcast of the presentation will be available under the [investor relations](#) section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas. We have three primary proprietary investigational [clinical programs](#): [etrasimod](#) (APD334) in Phase 2 evaluation for ulcerative colitis, [APD371](#) entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and [ralinepag](#) (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH). Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636



To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-300377009.html>

SOURCE Arena Pharmaceuticals, Inc.

